This Article Abstract Full Text (PDF) Data Supplement Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wakino, S. Articles by Law, R. E. Search for Related Content PubMed PubMed Citation Articles by Wakino, S. Articles by Law, R. E. Related Collections Cell signalling/signal transduction Smooth muscle proliferation and differentiation Mechanism of atherosclerosis/growth factors

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:746.)
© 2001 American Heart Association, Inc.

Vascular Biology

Retinoids Inhibit Proliferation of Human Coronary Smooth Muscle Cells by Modulating Cell Cycle Regulators

Shu Wakino; Ulrich Kintscher; Sarah Kim; Simon Jackson; Fen Yin; Sunil Nagpal; Roshantha A. S. Chandraratna; Willa A. Hsueh; Ronald E. Law

From the Division of Endocrinology, Diabetes, and Hypertension, School of Medicine, University of California, Los Angeles (S.W., U.K., S.K., S.J., F.Y., W.A.H., R.E.L.); the Department of Medicine/Cardiology, Virchowklinikum, Humboldt University Berlin and German Heart Institute, Berlin, Germany (U.K.); and Retinoid Research, Allergan Inc, Irvine, Calif (S.N., R.A.S.C.).

Correspondence to Ronald E. Law, PhD, UCLA School of Medicine, Division of Endocrinology, Diabetes, and Hypertension, Warren Hall, Second Floor, Suite 24-130, 900 Veteran Ave, Box 957073, Los Angeles, CA 90095. E-mail rlaw{at}mednet.ucla.edu

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Abstract—Retinoids inhibit rat vascular smooth muscle cell (VSMC) proliferation in vitro and intimal hyperplasia in vivo. We examined the mechanism of the antiproliferative effect of retinoids on human coronary artery smooth muscle cells (human CASMCs). The RAR ligands all-trans-retinoic acid (atRA) and ethyl-p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-l-propenyl]-benzoic acid (TTNPB); a pan-RXR/RAR agonist, 9-cis-retinoic acid (9cRA); and the RXR-selective ligand AGN4204 all inhibited DNA synthesis stimulated with platelet-derived growth factor and insulin (IC₅₀: TTNPB 63 nmol/L, atRA 120 nmol/L, AGN4204 460 nmol/L, 9cRA 1.5 µmol/L). All retinoids blocked cell cycle progression as determined by flow cytometry and inhibited retinoblastoma protein (Rb) phosphorylation. TTNPB, atRA, and AGN4204 inhibited the mitogenic induction of cyclin D1, whereas 9cRA had no effect. None of the retinoids affected the expression of CDK 2, 4, or 6 or cyclin E. All retinoids attenuated mitogen-induced downregulation of CDKI p27^Kip1, a major negative regulator of Rb phosphorylation, partly through stabilizing p27^Kip1 turnover. These data demonstrate that retinoids have antiproliferative activity by modulating G₁ S cell cycle regulators in human CASMCs through inhibition of Rb phosphorylation and elevation of p27^Kip1 levels.

Key Words: retinoid • human coronary smooth muscle cell • p27^Kip1, Rb • cell cycle

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Mechanical injury to the vessel wall induces the dedifferentiation, growth, and migration of medial smooth muscle cells (SMCs), which results in the formation of a neointima.¹ Proliferation of vascular SMCs (VSMCs) plays a critical role in the development of restenosis after coronary angioplasty and in the progression of fatty streaks to atherosclerotic plaques.^{2 3} After injury to the endothelium, VSMCs migrate into the intimal layer of the arterial wall, where they transition from a quiescent state and reenter the cell cycle in response to growth factors and cytokines.^{1 4}

Progression through the mammalian mitotic cycle is coordinated by expression and/or activation of multiple holoenzymes composed of a catalytic cyclin-dependent kinase (CDK) and a cyclin-regulatory subunit.⁵ Different cyclin/CDK complexes are temporally activated at specific phases of the cell cycle. Progression through the first gap phase (G₁) requires cyclin D–dependent kinase (CDK4 and CDK6) and cyclin E/CDK2 activity.⁵ Functional cyclin A/CDK2 is assembled and activated in late G₁ and during DNA synthesis (S phase).⁵ The kinase activity of the cyclin/CDK complexes can be negatively regulated by CDK-inhibitory proteins (CDKI), including p15^INK4b, p16^INK4a, p21^Cip1, and p27^Kip1.⁶ Cyclin/CDK holoenzymes phosphorylate the retinoblastoma tumor suppressor protein (Rb), resulting in inactivation of Rb and release of sequestered E2F transcription factors.⁷ E2F induces the transcription of genes encoding proteins that are required for S-phase DNA synthesis.⁸ These proteins have been shown to be upregulated in several animal models of angioplasty.⁹

All-trans-retinoic acid (atRA), a ligand for the nuclear receptor retinoic acid receptor (RAR), inhibits VSMC proliferation in vitro and neointima formation after mechanical injury.^{10 11 12 13 14 15 16} 9-cis-Retinoic acid (9cRA), a pan-agonist for RAR and retinoid X receptor (RXR) families of nuclear receptors, also inhibits VSMC proliferation.^{10 12} The molecular mechanism by which retinoids exert their antiproliferative activity toward VSMCs, however, has not been elucidated. Moreover, because VSMCs express at least 5 of the 6 isoforms that compose the RAR and RXR families,¹⁰ it is not clear which retinoid receptor(s) mediates the inhibition of VSMC growth. The purpose of the present study was to determine the mechanism by which retinoids inhibit VSMC proliferation by examining their effect on cell cycle regulators in human coronary artery SMCs (human CASMCs).

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Materials
Platelet-derived growth factor (PDGF)-BB, DMSO, atRA, 9cRA, ethyl-p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-l-propenyl]-benzoic acid (TTNPB), and cycloheximide were purchased from Sigma Chemical Co. AGN4204 was kindly provided by Allergan Inc. Human recombinant insulin was obtained from Lilly. Bromodeoxyuridine (BrdU) labeling and detection kit II was from Boehringer Mannheim. Hybond enzyme-linked chemiluminescence nitrocellulose membrane, horseradish peroxidase–linked anti-rabbit and anti-mouse antibodies, and enzyme-linked chemiluminescence Western blotting detection reagents were from Amersham Pharmacia Biotech. Human CASMCs and SMC growth medium-2 (SmGM-2) were obtained from Clonetics.

Cell Culture
Early passage (fourth to ninth) human CASMCs were grown to 60% to 70% confluence in SmGM-2 containing 5% FBS, 2 ng/mL human basic fibroblast growth factor, 0.5 ng/mL human epidermal growth factor, 50 µg/mL gentamicin, 50 ng/mL amphotericin-B, and 5 µg/mL bovine insulin. For all data shown, individual experiments were performed from separate vials of CASMCs.

Measurement of DNA Synthesis
Incorporation of the thymidine analogue BrdU was measured as previously described.¹⁷ Human CASMCs were plated at 3.0x10⁵ cells on 24-well plates, and after serum starvation (0.4% serum) for 48 hours, cells were stimulated with growth factors (PDGF 20 ng/mL + insulin 1 µmol/L [P+I]) in the presence or absence of retinoids for the next 20 hours. Then 15 µmol/L BrdU was added, and incubation was continued for another 4 hours. Cell nuclei incorporating BrdU appeared brown and were counted in high-power fields. Data were based on 6 different experiments from 3 separate vials of CASMCs.

Cell Cycle Distribution
Flow cytometry was performed to analyze cell cycle distribution. Quiescent human CASMCs were pretreated for 30 minutes with each compound or vehicle (DMSO), followed by the addition of growth factors. After 24 hours, cells were stained and processed as previously described.¹⁸ DNA histogram analysis was performed with ModFitLT software (Becton Dickinson). Experiments were repeated at least 3 times.

Western Blots
Preparation of cell lysates and Western immunoblotting were performed as previously described.¹⁸ Specific antibodies against phospho-Rb Ser 807/811 (No. 9308S, New England Biolabs Inc), cyclin D1 (sc-481, Santa Cruz Biotechnology), cyclin E (sc-753, Santa Cruz), cyclin A (sc-751, Santa Cruz), CDK 2 (sc-6248, Santa Cruz), CDK 4 (sc-749, Santa Cruz), CDK 6 (sc-7181, Santa Cruz), and CDKI p27^Kip1 (sc-1641, Santa Cruz) were used at a 1:200 concentration. Specific antibodies against RAR- (sc-481, Santa Cruz), RAR-ß (sc-753, Santa Cruz), RAR- (sc-751, Santa Cruz), RXR- (sc-6248, Santa Cruz), RXR-ß (sc-749, Santa Cruz), RXR- (sc-7181, Santa Cruz), elastin (clone BA-4, Sigma), and osteopontin (AF808, R&D Systems Inc) were used at a 1:100 concentration. The Western blots were quantified by densitometry.

Statistics
ANOVA was performed for statistical analysis. Values of P<0.05 were considered to be statistically significant. Data were expressed as mean±SEM.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Phenotypic Characterization of Human CASMCs
VSMCs isolated from tissue spontaneously change their phenotype when cultured in vitro.¹⁹ Quiescent medial VSMCs display a "contractile" phenotype characterized by high-level expression of contractile apparatus–associated proteins.¹⁹ When VSMCs switch from the contractile to the "synthetic" phenotype, levels of contractile proteins decrease, whereas genes that contribute to extracellular matrix production are upregulated.¹⁹ Human CASMCs expressed 2 markers of the synthetic phenotype, osteopontin and elastin, at relatively constant levels from passages 4 to 9 (data not shown). As in previous studies in rat VSMCs, human CASMCs expressed 5 of the 6 retinoid receptor subtypes, with only RXR- absent (data not shown).¹⁰

Retinoids Inhibit Mitogen-Induced DNA Synthesis in Human CASMCs
The results given in Figure 1 show that all retinoids tested inhibited DNA synthesis in quiescent human CASMCs stimulated with P+I for 24 hours. All retinoids attenuated DNA synthesis in a dose-dependent manner with IC₅₀s of 63 nmol/L for TTNPB, 120 nmol/L for atRA, 460 nmol/L for AGN4204, and 1.5 µmol/L for 9cRA. Significant inhibitory effects were observed at 20 nmol/L for atRA and TTNPB and at 200 nmol/L for 9cRA and AGN4204. The RAR-selective ligands TTNPB and atRA were more potent inhibitors of DNA synthesis than the RXR-selective ligands AGN4204 and 9cRA. Interestingly, whereas AGN4204 had modest inhibitory effects at concentrations of 2 and 20 nmol/L (10±9.2% and 18±8.7% inhibition, respectively), enhanced antimitogenic activity was observed at 200 nmol/L and 2 µmol/L (42±10% and 65±13% inhibition, respectively), which approached those of atRA and TTNPB.

View larger version (37K): [in this window] [in a new window]   Figure 1. Retinoids inhibit mitogen-induced DNA synthesis in human CASMCs. Quiescent human CASMCs were stimulated by treatment with P+I. Cells were preincubated with TTNPB, atRA, AGN4204, and 9cRA in the range of 2 nmol/L to 2 µmol/L for 30 minutes before addition of mitogens. Incorporation of BrdU was measured as described in Methods. Results are from 6 independent experiments and are presented as mean±SEM, *P<0.05, **P<0.01 vs mitogen-stimulated cells.

Retinoids Block the Progression of Human CASMCs Into S Phase
All retinoids inhibited cell cycle progression at the highest concentration tested (2 µmol/L) as determined by flow cytometry (Figure I, please see http://www.atvb.ahajournals.org). Subconfluent human CASMCs accumulated in G₁ after serum starvation for 24 hours (85.8% in G₀/G₁ phase and 10.2% in S phase, Figure I-A). Quiescent CASMCs were induced to enter S phase by stimulation with the competence factor PDGF (20 ng/mL) and a progression factor insulin (1 µmol/L) (P+I). The population of G₀/G₁ cells decreased substantially (70.6%, Figure I-B), with a concomitant increase in CASMCs in S phase (26.4%; Figure I-B). The RAR ligands TTNPB and atRA inhibited G₁S progression, as reflected by the higher percentage of G₀/G₁ cells and by the lower percentage of S-phase cells (Figure I-C and I-D). Movement of cells from G₁S was also inhibited by the RXR-selective ligand AGN4204 and the RAR and RXR pan-agonist 9cRA (Figure I-E and I-F, respectively). Rank order potency for the blockade of G₁ exit by different retinoids was the same as observed for their inhibition of DNA synthesis (TTNPB > atRA > AGN4204 > 9cRA; Figure II, please see http://www.atvb.ahajournals.org).

Retinoids Inhibit Mitogen-Induced Rb Phosphorylation in Human CASMCs
To elucidate the mechanism by which retinoids inhibit the proliferation of human CASMCs, we examined their effect on Rb phosphorylation, because hyperphosphorylation of Rb is required for G₁S progression in most mammalian cells.⁷ Phospho-specific antibodies were used to assess the phosphorylation status of Ser 807/811 in Rb, which are important CDK-dependent functional sites in this G₁ regulatory protein.²⁰ All retinoids inhibited the mitogen-induced phosphorylation at Ser 807/811. TTNPB and atRA attenuated Rb phosphorylation at 20 nmol/L (46±6.6% and 33±9.4% inhibition, respectively, P<0.05 versus P+I alone, Figure 2A and 2B) to 2 µmol/L (86±5.4% and 71±8.6% inhibition, respectively, P<0.01 versus P+I alone, Figure 2A and 2B). AGN4204 had a modest inhibitory effect at 200 nmol/L (38±9.7% inhibition, P<0.01 versus P+I alone, Figure 2C) but substantially inhibited Rb phosphorylation at 2 µmol/L (68±8.0% inhibition: P<0.01 versus P+I alone, Figure 2C). 9cRA attenuated the phosphorylation of Rb significantly only at 2 µmol/L (48±17% inhibition, P<0.05 versus P+I alone, Figure 2D). These data are concordant with the potency of each retinoid to inhibit DNA synthesis and cell cycle progression, which suggests that their antiproliferative activity results from the prevention of Rb phosphorylation required for transit from G₁ into S phase. Similar results were obtained with 10% serum used as a mitogen (Figure III, please see http://www.atvb.ahajournals.org).

View larger version (36K): [in this window] [in a new window]   Figure 2. Retinoids inhibit mitogen-induced Rb phosphorylation in human CASMCs. Cells were treated as described in Figure 1. After 24 hours, whole-cell proteins (35 µg) were assayed by Western immunoblotting with anti–phospho Rb Ser 807/811 antibody (top). Each blot is representative of 3 separate experiments. Densitometric analysis of immunoblots is shown as % of mitogen-stimulated cells (bottom). Results are presented as mean±SEM (n=3), *P<0.05, **P<0.01 vs mitogen-stimulated cells.

Effects of Retinoids on G₁ Cyclins and CDK Expression in Human CASMCs
To understand the mechanism by which retinoids inhibit Rb phosphorylation, we examined their effect on the expression of CDKs and their cyclin partners for which Rb is a major physiological substrate. CDK2 levels were low in quiescent cells, increased after 24 hours of mitogenic stimulation, and did not change with any of these compounds (data not shown). Quiescent human CASMCs expressed both CDK4 and CDK6, which did not change after either mitogenic stimulation or treatment with any of these compounds (data not shown). Cyclin D1 was expressed at low levels in quiescent CASMCs and increased 2.0±0.1-fold after 24 hours of stimulation with P+I (Figure IV, please see http://www.atvb.ahajournals.org). The RAR ligands TTNPB and atRA both inhibited the mitogenic induction of cyclin D1 protein (TTNPB: 2 nmol/L, 63±9.3% inhibition; 2 µmol/L, 79±11% inhibition, both P<0.01 versus P+I alone; atRA: 200 nmol/L, 58±7.0% inhibition, P<0.05 versus P+I alone; 2 µmol/L, 72±2.9% inhibition, P<0.01 versus P+I alone, Figure IV-A and IV-B). In contrast, RXR ligands had minimal effect on cyclin D1 expression. AGN4204 inhibited the induction of cyclin D1 only at 2 µmol/L, the highest concentration tested (71±9.7% inhibition, P<0.05 versus P+I alone, Figure IV-C), whereas 9cRA had no effect (Figure IV-D). None of the retinoids affected the mitogenic induction of cyclin E (data not shown).

Cyclin A is essential for cell cycle progression in S phase, and its expression is regulated through the E2F transcription factor, whose activity is controlled by the phosphorylation status of Rb. In quiescent human CASMCs, low levels of cyclin A protein were detected, which increased 3.7±0.4-fold after mitogenic stimulation for 24 hours. Consistent with the inhibitory effects on Rb phosphorylation, each retinoid attenuated the induction of cyclin A (Figure V, please see http://www.atvb.ahajournals.org).

Retinoids Prevent Mitogen-Induced Downregulation of p27^Kip1 in Human CASMCs
The CDKI p27^Kip1 inhibits the activities of cyclin E/CDK2 and cyclin D1/CDK4 complexes.²¹ Downregulation of p27^Kip1 during G₁ in response to mitogens is important for maximal activation of G₁ cyclin/CDK holoenzymes.⁹ We therefore investigated the effect of these compounds on p27^Kip1 expression after mitogenic stimulation of human CASMCs with P+I. Quiescent G₀/G₁ CASMCs express substantial levels of p27^Kip1 protein. Expression of p27^Kip1 decreased markedly after 24 hours of stimulation with P+I. Each retinoid tested significantly attenuated mitogen-induced downregulation of p27^Kip1. TTNPB and atRA attenuated mitogen-induced downregulation of p27^Kip1 at 200 nmol/L to 2 µmol/L (TTNPB: 200 nmol/L, 88±5.3% of quiescent cells; 2 µmol/L, 89±1.2% of quiescent cells, both P<0.01 versus P+I alone; atRA: 200 nmol/L, 91±6.8% of quiescent cells; 2 µmol/L, 92±8.8% of quiescent cells, both P<0.01 versus P+I alone, Figure 3A and 3B). AGN4204 and 9cRA also prevented downregulation of p27^Kip1 (AGN4204: 200 nmol/L, 76±4.0% of quiescent cells, P<0.05 versus P+I alone; 2 µmol/L, 99±7.9% of quiescent cells, P<0.01 versus P+I alone; 9cRA: 200 nmol/L, 75±8.7% of quiescent cells, P<0.05 versus P+I alone; 2 µmol/L, 80±6.7% of quiescent cells, P<0.01 versus P+I alone, Figure 3C and 3D).

View larger version (27K): [in this window] [in a new window]   Figure 3. Retinoids prevent mitogen-induced downregulation of CDKI p27Kip1 in human CASMCs. Cells were treated as described in Figure 1. After 24 hours, whole-cell proteins (35 µg) were assayed by Western immunoblotting with anti-p27Kip1 antibody (top). Each blot is representative of 3 separate experiments. Densitometric analysis of immunoblots is shown as % of quiescent cells (bottom). Results are presented as mean±SEM (n=3), *P<0.05, **P<0.01 vs mitogen-stimulated cells.

To delineate the mechanism by which retinoids increased p27^Kip1 levels, we examined its turnover in mitogen-stimulated human CASMCs. After treatment of cells with P+I plus or minus retinoids for 6 hours to permit a determination of p27 ^Kip1 half-life, cycloheximide (20 µg/mL) was added to inhibit de novo protein synthesis. Selection of this protocol was based on the previous observation by Miano et al¹⁰ that antiproliferative activity of retinoids was exerted within the first 6 hours after mitogenic stimulation. Steady-state levels of p27 ^Kip1 protein were determined by Western blot at various times after inhibition of protein synthesis (Figure 4A). The half-life of p27^Kip1 protein in mitogen-stimulated cells was calculated at 10.7 hours, which is similar to that reported by Servant et al²² for PDGF-stimulated rat aortic SMCs. In contrast, pretreatment with retinoids substantially prolonged the half-life of p27^Kip1 (44.9 hours for TTNPB, 35.1 hours for atRA, 25.9 hours for AGN4204, and 19.7 hours for 9cRA; Figure 4B). In addition, retinoid-treated VSMCs accumulated higher-molecular-weight, putatively ubiquitinated forms of p27 ^Kip1 (indicated by small arrows in Figure 4A).

View larger version (35K): [in this window] [in a new window]   Figure 4. Retinoids prevent mitogen-induced protein degradation of CDKI p27Kip1 in human CASMCs. Cells were treated as described in Figure 1. Cycloheximide was added 6 hours after the addition of mitogen plus or minus retinoids. Steady-state levels of p27Kip1 protein were determined by immunoblotting at various times after inhibition of de novo protein synthesis (A). Each autoradiogram is representative of 3 separate experiments. B, The intensity of bands was quantified and plotted as log(% of control) (0 hours). The data represent the mean of 3 independent experiments.

Levels of CDKI p15^INK4b or p16^INK4a did not change after either mitogenic stimulation or retinoid treatment (data not shown). In marked contrast to p27^Kip1, mitogenic stimulation of human CASMCs increased levels of the CDKI p21^Cip1, which was attenuated by retinoids (data not shown). Mitogenic induction of p21^Cip1 has been observed in a variety of mammalian cell lineages, but its relevance to cell cycle progression is controversial.²³

These results suggest that all retinoids block G₁S progression of CASMCs and Rb phosphorylation, at least in part, through their effect to antagonize p27^Kip1 downregulation after exposure of human CASMCs to mitogens.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
Proliferating mammalian cells pass through several cell cycle checkpoints, mainly G₁-to-S and G₂-to-M transitions. In this study, we demonstrated that all retinoids block cell cycle progression at the G₁S transition, attenuate Rb phosphorylation, and upregulate p27^Kip1 levels. In addition, RAR-selective but not RXR-selective retinoids were potent inhibitors of mitogen-induced cyclin D1. Targeting G₁ cell cycle regulators by retinoids supports the prior observation of Miano et al that the antiproliferative activity of atRA was substantially diminished when its administration to quiescent rat VSMCs was delayed 6 to 12 hours (ie, G₁ phase) after mitogenic stimulation with PDGF.¹⁰

Hyperphosphorylation of Rb by G₁ cyclin/CDKs is required for cells to enter S phase.⁷ Rb contains multiple CDK phosphorylation sites that regulate its conformation and ability to bind other cell cycle regulatory protein, such as E2F.²⁴ Of the 16 potential CDK phosphorylation sites in Rb, Ser 807/811 has been shown to play a critical role in the growth-suppressive function of Rb.^{20 24} Consistent with their activity to inhibit G₁ exit of human CASMCs, retinoids blocked mitogen-induced phosphorylation of Ser 807/811 in Rb.

To elucidate the mechanism by which retinoids inhibit mitogen-induced Rb phosphorylation, we examined their effect on the expression of G₁ cyclins and CDKs, which, as holoenzymes, phosphorylate Rb. Previous studies have shown that a variety of growth factors induce expression of cyclin D, the G₁ cyclin that partners with CDK4 or CDK6, which is essential for cell proliferation.²⁵ The RAR-selective ligands atRA and TTNPB potently inhibited cyclin D1 induction by P+I. In marked contrast, RXR-selective ligands had either a modest effect (AGN4204) or no effect (9cRA) on the mitogenic induction of cyclin D1. These data are consistent with an RAR pathway–dependent mechanism for inhibiting cyclin D1 expression.¹² Selective targeting of cyclin D1 expression by RAR-selective ligands may account for their having a greater antiproliferative activity than RXR-selective ligands in human CASMCs. Transcriptional activation of the cyclin D promoter by growth factors is mediated, at least in part, through the AP-1 binding site at -954, which could be negatively regulated by RAR transrepression of AP-1 activity.^{26 27} Blockade of cell cycle progression by retinoids, however, cannot be fully explained by the effect on cyclin D1 because RXR-selective ligands inhibited human CASMC proliferation at concentrations that had no effect on mitogen-induced upregulation of cyclin D1.

Another logical target for the antiproliferative activity of retinoids is CDKIs, which negatively regulate the activity of multiple cyclin/CDK complexes.⁶ The CDKI p27^Kip1 plays a pivotal role in the control of cell proliferation by inhibiting both CDK2 and CDK4 activity. Overexpression of p27^Kip1 causes cell cycle arrest in G₁ phase in both vascular and nonvascular cells.^{28 29} Quiescent VSMCs express high levels of p27^Kip1. After mitogenic stimulation, p27^Kip1 levels decline precipitously and VSMCs enter S phase to initiate DNA synthesis.⁹ As in those studies, we showed that levels of p27^Kip1 substantially decreased 24 hours after mitogenic stimulation of human CASMCs. Treatment with either RAR-selective or RXR-selective retinoids attenuated the mitogen-induced downregulation of p27^Kip1 and restored levels of this CDKI approaching that observed in quiescent CASMCs. The rank order potency of retinoids for preventing p27^Kip1 downregulation closely mirrored their activity to inhibit DNA synthesis with atRA > TTNPB > AGN 4204 > 9cRA. In combination, these data strongly suggest that the inhibition of mitogen-induced downregulation of p27^Kip1 is a major mechanism by which retinoids prevent Rb hyperphosphorylation and block G₁S progression of human CASMCs.

Regulation of p27^Kip1 levels during the cell cycle occurs predominantly through posttranslational mechanisms.³⁰ Cyclin E/CDK2–mediated phosphorylation of p27^Kip1 at threonine 187 targets it for degradation through the ubiquitin-proteasome system.³¹ This pathway is active in proliferating cells but is markedly downregulated when cycling cells exit into G₀/G₁ from the quiescent state, which substantially increases p27^Kip1 half-life.³² In this study, we demonstrated that RAR-selective retinoids increased p27^Kip1 half-life 4-fold after mitogen stimulation, whereas RXR-selective ligands increased it 2-fold. Retinoid-treated VSMCs also accumulated higher-molecular-weight, putatively ubiquitinated forms of p27^Kip1 similar to that observed in mammalian cells exposed to proteasome-specific inhibitors.³³ Thus, stabilization of p27^Kip1 by retardation of its proteasome-mediated degradation accounts, at least in part, for the action of retinoids to antagonize p27^Kip1 downregulation by mitogens.

Although not explored in the present investigation, retinoids may also affect transcriptional regulation of p27^Kip1 as an additional mechanism for elevating levels in human CASMCs. In rat aortic VSMCs, PDGF induces a rapid and transient inhibition of p27^Kip1 gene transcription, in addition to activating the proteasome degradation pathway.²² Activation of the p27^Kip1 promoter by atRA or 9cRA has been observed during retinoid-mediated neuronal differentiation of human neuroblastoma tumor cells³³ and mouse embryonal carcinoma cells.³⁴ Direct induction of p27^Kip1 transcription by retinoids through a cognate retinoic acid response element (RARE), however, has not been reported. Further investigations are necessary to define interactions between mitogenic and retinoid receptor signaling pathways that regulate p27^Kip1 transcription during G₁ phase of the cell cycle.

Recent studies in a variety of animal models have demonstrated a beneficial effect of retinoids on vascular remodeling in response to injury. AtRA suppressed neointimal formation in rat carotid arteries after balloon catheterization^{11 13 14} and restenosis after angioplasty in atherosclerotic femoral arteries in rabbits.¹⁵ Intimal hyperplasia in rabbit after interposition of jugular vein bypass grafts to the carotid artery was also substantially attenuated by atRA.¹⁶ Inhibition of intimal thickening by atRA was hypothesized to result from decreased VSMC proliferation and/or migration. Reduced BrdU incorporation or lower proliferating cell nuclear antigen labeling indices provided additional evidence for impaired cell cycle progression by SMCs in the injured vessel wall.^{11 13 16} The present study provides a mechanistic explanation for the observed in vivo antiproliferative activity of RAR-selective retinoids. Tanner et al⁹ documented a rapid and sharp decline in p27^Kip1 protein levels after mechanical injury of porcine femoral arteries. No significant changes in other CDKIs were observed until much later times postinjury, when substantial neointima had already formed. Elevation of p27^Kip1 levels by activating RAR receptors, therefore, may block one of the earliest steps in the injury response prerequisite for VSMC proliferation. Interestingly, the macrolide antibiotic rapamycin, which inhibits VSMC proliferation by blocking the G₁S transition, was recently shown to reduce intimal thickening in porcine coronary arteries after angioplasty by increasing p27^Kip1 levels and lowering Rb phosphorylation in vessels.³⁵

We observed that 9cRA, which can activate both RAR and RXR, and the RXR-selective agonist AGN4204 are less potent inhibitors of human CASMC proliferation than RAR-selective retinoids. The marked difference in the antiproliferative activity of these 2 major retinoid receptor subtypes may be due to the lack of a substantial effect of RXR-selective compounds on mitogen-induced cyclin D1 expression. By comparison to studies testing RAR-selective retinoids, there is scant evidence that activated RXR confers vascular protection in vivo. Inferential support for RXR vascular activity is provided by our recent findings that activation of peroxisome proliferator–activated receptor- (PPAR-), which heterodimerizes with RXR-, inhibits G₁S progression in rat VSMCs.¹⁸ In accordance with our present findings for RXR-selective retinoids, PPAR- ligands also attenuated Rb hyperphosphorylation and p27^Kip1 downregulation and had no effect on cyclin D1.¹⁸ Moreover, PPAR- ligands suppress neointimal formation after injuring the endothelium in rats.^{17 36} Thus, although only atRA has been tested and shown to inhibit intimal hyperplasia in an animal model of vessel wall injury,^{11 13} similar studies are warranted for RXR-selective retinoids based on the in vivo activity of PPAR- ligands. Significant differences in the vascular activity of RXR- versus PPAR- ligands, however, would not be surprising, because RXR- is a promiscuous partner for multiple nuclear receptors (vitamin D receptor, thyroid hormone receptor, PPAR-, etc).

A wide variety of antiproliferative drugs are currently being investigated for the prevention of restenosis. Adenoviral expression vectors have been used to deliver a cell cycle regulatory gene directly into the arterial wall. Infection of porcine femoral or rat carotid arteries with an adenoviral vector expressing a nonphosphorylatable, constitutively active form of Rb inhibited neointimal formation in animal balloon-injury models.⁴ Similarly, adenoviral overexpression of p27^Kip1 but not p16^INK4b markedly attenuated intimal hyperplasia after balloon injury of porcine femoral arteries.³⁷ AtRA has already been shown to inhibit rat VSMC growth induced by PDGF in vitro¹⁰ and neointimal formation in rat carotid artery after balloon injury.¹¹ In the present study, we demonstrated that the antiproliferative activity of retinoids toward VSMCs resulted from their perturbing the function of the key cell cycle regulators, Rb, cyclin D1, and p27^Kip1. By modulating these cell cycle molecules in human coronary arterial cells, natural retinoids or synthetic analogues may provide a novel therapeutic treatment for proliferative vascular diseases.

	Acknowledgments

 
This work was supported by National Institutes of Health grant HL-58328-03 to W.A.H. S.W. was supported by a fellowship from the Mary K. Iacocca Foundation. U.K. was supported by a research fellowship from the Gonda (Goldschmied) Diabetes Center, University of California, Los Angeles.

Received January 24, 2001; accepted February 7, 2001.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Schwartz SM, deBlois D, O’Brien ER. The intima: soil for atherosclerosis and restenosis. Circ Res. 1995;77:445–465.[Free Full Text]

2. Hanke H. Proliferative response of smooth muscle cells after experimental balloon angioplasty. Circulation. 1996;93:202.

3. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol. 1995;57:791–804.[Medline] [Order article via Infotrieve]

4. Braun DR, Mann MJ, Dzau VJ. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation. 1998;98:82–89.[Abstract/Free Full Text]

5. Sherr CJ. G1 phase progression: cycling on cue. Cell. 1994;79:551–555.[Medline] [Order article via Infotrieve]

6. Morgan DO. Principles of CDK regulation. Nature. 1995;374:131–134.[Medline] [Order article via Infotrieve]

7. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323–330.[Medline] [Order article via Infotrieve]

8. Nevins JR, Leone G, DeGregori J, Jakoi L. Role of the Rb/E2F pathway in cell growth control. J Cell Physiol. 1997;173:233–236.[Medline] [Order article via Infotrieve]

9. Tanner FC, Yang ZY, Duckers E, Gordon D, Nabel GJ, Nabel EG. Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ Res. 1998;82:396–403.[Abstract/Free Full Text]

10. Miano JM, Topouzis S, Majesky MW, Olson EN. Retinoid receptor expression and all-trans retinoic acid–mediated growth inhibition in vascular smooth muscle cells. Circulation. 1996;93:1886–1895.[Abstract/Free Full Text]

11. Miano JM, Kelly LA, Artacho CA, Nuckolls TA, Piantedosi R, Blaner WS. all-Trans-Retinoic acid reduces neointimal formation and promotes favorable geometric remodeling of the rat carotid artery after balloon withdrawal injury. Circulation. 1998;98:1219–1227.[Abstract/Free Full Text]

12. Chen S, Gardner DG. Retinoic acid uses divergent mechanisms to activate or suppress mitogenesis in rat aortic smooth muscle cells. J Clin Invest. 1998;102:653–662.[Medline] [Order article via Infotrieve]

13. Neuville P, Yan Z, Gidlof A, Pepper MS, Hansson GK, Gabbiani G, Sirsjo A. Retinoic acid regulates arterial smooth muscle cell proliferation and phenotypic features in vivo and in vitro through an RAR-dependent signaling pathway. Arterioscler Thromb Vasc Biol. 1999;19:1430–1436.[Abstract/Free Full Text]

14. DeRose JJ Jr, Madigan J, Umana JP, Prystowsky JH, Nowygrod R, Oz MC, Todd GJ. Retinoic acid suppresses intimal hyperplasia and prevents vessel remodeling following arterial injury. Cardiovasc Surg. 1999;7:633–639.[Medline] [Order article via Infotrieve]

15. Wiegman PJ, Barry WL, McPherson JA, McNamara CA, Gimple LW, Sanders JM, Bishop GG, Powers ER, Ragosta M, Owens GK, Sarembock IJ. All-trans-retinoic acid limits restenosis after balloon angioplasty in the focally atherosclerotic rabbit: a favorable effect on vessel remodeling. Arterioscler Thromb Vasc Biol. 2000;20:89–95.[Abstract/Free Full Text]

16. Leville CD, Osipov VO, Jean-Claude JM, Seabrook GR, Towne JB, Cambria RA. All-trans-retinoic acid decreases cell proliferation and increases apoptosis in an animal model of vein bypass grafting. Surgery. 2000;128:178–184.[Medline] [Order article via Infotrieve]

17. Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest. 1996;98:1897–1905.[Medline] [Order article via Infotrieve]

18. Wakino S, Kintscher U, Kim S, Yin F, Hsueh WA, Law RE. Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1 S transition in vascular smooth muscle cells. J Biol Chem. 2000;275:22435–22441.[Abstract/Free Full Text]

19. Shanahan CM, Weissberg PL. Smooth muscle cell heterogeneity: patterns of gene expression in vascular smooth muscle cells in vitro and in vivo. Arterioscler Thromb Vasc Biol. 1998;18:333–338.[Abstract/Free Full Text]

20. Driscoll B, T’Ang A, Hu YH, Yan CL, Fu Y, Luo Y, Wu KJ, Wen S, Shi XH, Barsky L, Weinberg K, Murphree AL, Fung YK. Discovery of a regulatory motif that controls the exposure of specific upstream cyclin-dependent kinase sites that determine both conformation and growth suppressing activity of pRb. J Biol Chem. 1999;274:9463–9471.[Abstract/Free Full Text]

21. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 1994;78:67–74.[Medline] [Order article via Infotrieve]

22. Servant MJ, Coulombe P, Turgeon B, Meloche S. Differential regulation of p27^Kip1 expression by mitogenic and hypertrophic factors: involvement of transcriptional and posttranscriptional mechanisms. J Cell Biol. 2000;148:543–556.[Abstract/Free Full Text]

23. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 1994;54:3391–3395.[Abstract/Free Full Text]

24. Knudsen ES, Wang JY. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem. 1996;271:8313–8320.[Abstract/Free Full Text]

25. Pestell RG, Albanese C, Reutens AT, Segall JE, Lee RJ, Arnold A. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev. 1999;20:501–534.[Abstract/Free Full Text]

26. Herber B, Truss M, Beato M, Muller R. Inducible regulatory elements in the human cyclin D1 promoter. Oncogene. 1994;9:1295–1304.[Medline] [Order article via Infotrieve]

27. Nicholson RC, Mader S, Nagpal S, Leid M, Rochette EC, Chambon P. Negative regulation of the rat stromelysin gene promoter by retinoic acid is mediated by an AP1 binding site. EMBO J. 1990;9:4443–4454.[Medline] [Order article via Infotrieve]

28. Tikoo R, Osterhout DJ, Casaccia BP, Seth P, Koff A, Chao MV. Ectopic expression of p27^Kip1 in oligodendrocyte progenitor cells results in cell-cycle growth arrest. J Neurobiol. 1998;36:431–40.[Medline] [Order article via Infotrieve]

29. Braun-Dullaeus RC, Mann MJ, Ziegler A, von der Leyen HE, Dzau VJ. A novel role for the cyclin-dependent kinase inhibitor p27(Kip1) in angiotensin II-stimulated vascular smooth muscle cell hypertrophy. J Clin Invest. 1999;104:815–823.[Medline] [Order article via Infotrieve]

30. Hengst L, Reed SI. Translational control of p27^Kip1 accumulation during the cell cycle. Science. 1996;271:1861–1864.[Abstract]

31. Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, Pagano M. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev. 1999;13:1181–1189.[Abstract/Free Full Text]

32. Pagano M, Tam SW, Theodoras AM, Beer RP, Del SG, Chau V, Yew PR, Draetta GF, Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 1995;269:682–685.[Abstract/Free Full Text]

33. Borriello A, Pietra VD, Criscuolo M, Oliva A, Tonini GP, Iolascon A, Zappia V, Ragione FD. p27^Kip1 accumulation is associated with retinoic-induced neuroblastoma differentiation: evidence of a decreased proteasome-dependent degradation. Oncogene. 2000;19:51–60.[Medline] [Order article via Infotrieve]

34. Sasaki K, Tamura S, Tachibana H, Sugita M, Gao Y, Furuyama J, Kakishita E, Sakai T, Tamaoki T, Hashimoto-Tamaoki T. Expression and role of p27(Kip1) in neuronal differentiation of embryonal carcinoma cells. Brain Res Mol Brain Res. 2000;77:209–221.[Medline] [Order article via Infotrieve]

35. Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S, Chesebro J, Fallon J, Fuster V, Marks A, Badimon JJ. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 1999;99:2164–2170.[Abstract/Free Full Text]

36. Yoshimoto T, Naruse M, Shizume H, Naruse K, Tanabe A, Tanaka M, Tago K, Irie K, Muraki T, Demura H, Zardi L. Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. Atherosclerosis. 1999;145:333–340.[Medline] [Order article via Infotrieve]

37. Tanner FC, Boehm M, Akyurek LM, San H, Yang ZY, Tashiro J, Nabel GJ, Nabel EG. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. Circulation. 2000;101:2022–2025. [Abstract/Free Full Text]

This article has been cited by other articles:

				T. Nomiyama, Y. Zhao, F. Gizard, H. M. Findeisen, E. B. Heywood, K. L. Jones, O. M. Conneely, and D. Bruemmer Deficiency of the NR4A Neuron-Derived Orphan Receptor-1 Attenuates Neointima Formation After Vascular Injury Circulation, February 3, 2009; 119(4): 577 - 586. [Abstract] [Full Text] [PDF]

				C. Wang, M. Han, X.-M. Zhao, and J.-K. Wen Kruppel-like Factor 4 is Required for the Expression of Vascular Smooth Muscle Cell Differentiation Marker Genes Induced by All-Trans Retinoic Acid J. Biochem., September 1, 2008; 144(3): 313 - 321. [Abstract] [Full Text] [PDF]

				D. K. Bowles, K. K. Maddali, V. C. Dhulipala, and D. H. Korzick PKC{delta} mediates anti-proliferative, pro-apoptic effects of testosterone on coronary smooth muscle Am J Physiol Cell Physiol, August 1, 2007; 293(2): C805 - C813. [Abstract] [Full Text] [PDF]

				N. Kada, T. Suzuki, K. Aizawa, T. Matsumura, N. Ishibashi, N. Suzuki, N. Takeda, Y. Munemasa, D. Sawaki, T. Ishikawa, et al. Acyclic Retinoid Inhibits Neointima Formation Through Retinoic Acid Receptor Beta-Induced Apoptosis Arterioscler Thromb Vasc Biol, July 1, 2007; 27(7): 1535 - 1541. [Abstract] [Full Text] [PDF]

				R. M. Day, Y. H. Lee, A.-M. Park, and Y. J. Suzuki Retinoic Acid Inhibits Airway Smooth Muscle Cell Migration Am. J. Respir. Cell Mol. Biol., June 1, 2006; 34(6): 695 - 703. [Abstract] [Full Text] [PDF]

				L. Ragolia, T. Palaia, C. E. Hall, J. K. Maesaka, N. Eguchi, and Y. Urade Accelerated Glucose Intolerance, Nephropathy, and Atherosclerosis in Prostaglandin D2 Synthase Knock-out Mice J. Biol. Chem., August 19, 2005; 280(33): 29946 - 29955. [Abstract] [Full Text] [PDF]

				J. Adams, E. Kiss, A. B.V. Arroyo, M. Bonrouhi, Q. Sun, Z. Li, N. Gretz, A. Schnitger, C. C. Zouboulis, M. Wiesel, et al. 13-cis Retinoic Acid Inhibits Development and Progression of Chronic Allograft Nephropathy Am. J. Pathol., July 1, 2005; 167(1): 285 - 298. [Abstract] [Full Text] [PDF]

				F. Blaschke, O. Leppanen, Y. Takata, E. Caglayan, J. Liu, M. C. Fishbein, K. Kappert, K. I. Nakayama, A. R. Collins, E. Fleck, et al. Liver X Receptor Agonists Suppress Vascular Smooth Muscle Cell Proliferation and Inhibit Neointima Formation in Balloon-Injured Rat Carotid Arteries Circ. Res., December 10, 2004; 95(12): e110 - e123. [Abstract] [Full Text] [PDF]

				J. Rius, J. Martinez-Gonzalez, J. Crespo, and L. Badimon Involvement of Neuron-Derived Orphan Receptor-1 (NOR-1) in LDL-Induced Mitogenic Stimulus in Vascular Smooth Muscle Cells: Role of CREB Arterioscler Thromb Vasc Biol, April 1, 2004; 24(4): 697 - 702. [Abstract] [Full Text] [PDF]

				J. M. Miano and B. C. Berk Retinoids: New Insight Into Smooth Muscle Cell Growth Inhibition Arterioscler Thromb Vasc Biol, May 1, 2001; 21(5): 724 - 726. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Data Supplement Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wakino, S. Articles by Law, R. E. Search for Related Content PubMed PubMed Citation Articles by Wakino, S. Articles by Law, R. E. Related Collections Cell signalling/signal transduction Smooth muscle proliferation and differentiation Mechanism of atherosclerosis/growth factors